BlueSky Immunotherapies has expanded and secured its intellectual property portfolio. The patents based on WO2015/063085 cover a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein and forms the basis of the company’s technology platform.

Corresponding patents were recently granted in (EP 3063273), USA (US 10480013), and China (CN 2019112100112140) covering key markets of the technology. Patent protection will be in force until 2034.